1 3767 112 INTEGRATIVE EPIGENOMIC ANALYSIS IN DIFFERENTIATED HUMAN PRIMARY BRONCHIAL EPITHELIAL CELLS EXPOSED TO CIGARETTE SMOKE. CIGARETTE SMOKE (CS) IS ONE OF THE MAJOR RISK FACTORS FOR MANY PULMONARY DISEASES, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND LUNG CANCER. THE FIRST LINE OF DEFENSE FOR CS EXPOSURE IS THE BRONCHIAL EPITHELIAL CELLS. ELUCIDATION OF THE EPIGENETIC CHANGES DURING CS EXPOSURE IS KEY TO GAINING A MECHANISTIC UNDERSTANDING INTO HOW MATURE AND DIFFERENTIATED BRONCHIAL EPITHELIAL CELLS RESPOND TO CS. THEREFORE, WE PERFORMED EPIGENOMIC PROFILING IN CONJUNCTION WITH TRANSCRIPTIONAL PROFILING IN WELL-DIFFERENTIATED HUMAN BRONCHIAL EPITHELIAL (HBE) CELLS CULTURED IN AIR-LIQUID INTERFACE (ALI) EXPOSED TO THE VAPOR PHASE OF CS. THE GENOME-WIDE ENRICHMENT OF HISTONE 3 LYSINE 27 ACETYLATION WAS DETECTED BY CHROMATIN IMMUNOPRECIPITATION FOLLOWED BY NEXT GENERATION SEQUENCING (CHIP-SEQ) IN HBE CELLS AND SUGGESTED THE PLAUSIBLE BINDING OF SPECIFIC TRANSCRIPTION FACTORS RELATED TO CS EXPOSURE. ADDITIONALLY, INTERROGATION OF CHIP-SEQ DATA WITH GENE EXPRESSION PROFILING OF HBE CELLS AFTER CS EXPOSURE FOR DIFFERENT DURATIONS (3 HOURS, 2 DAYS, 4 DAYS) SUGGESTED THAT EARLIER EPIGENETIC CHANGES (3 HOURS AFTER CS EXPOSURE) MAY BE ASSOCIATED WITH LATER GENE EXPRESSION CHANGES INDUCED BY CS EXPOSURE (4 DAYS). THE INTEGRATION OF EPIGENETICS AND GENE EXPRESSION DATA REVEALED SIGNALING PATHWAYS RELATED TO CS-INDUCED EPIGENETIC CHANGES IN HBE CELLS THAT MAY IDENTIFY NOVEL REGULATORY PATHWAYS RELATED TO CS-INDUCED COPD. 2018 2 158 23 ABERRANT P16 PROMOTER METHYLATION AMONG GREEK LUNG CANCER PATIENTS AND SMOKERS: CORRELATION WITH SMOKING. GENETIC AND ENVIRONMENTAL FACTORS (DIETARY AND SMOKING) INFLUENCE LUNG CANCER EPIDEMIOLOGY AND INDUCE EPIGENETIC MODIFICATIONS THAT SHOULD BE ASSESSED IN INDIVIDUAL POPULATIONS. WE ANALYZED P16 METHYLATION AMONG GREEK NON-SMALL CELL LUNG CARCINOMA PATIENTS AND SMOKERS USING TWO-STAGE METHYLATION-SPECIFIC POLYMERASE CHAIN REACTION. ONE HUNDRED AND FIFTY SPECIMENS FROM CANCEROUS AND ADJACENT NON-CANCEROUS TISSUE, BRONCHIAL WASHINGS AND SPUTUM FROM PATIENTS AND 48 SPECIMENS, MOSTLY SPUTUM, FROM DISEASE-FREE SMOKERS WERE INCLUDED. P16 METHYLATION WAS VERY FREQUENT IN BIOPSIES (82.85%) AND BRONCHIAL WASHINGS (NON-SMALL CELL LUNG CARCINOMA, 80.35%; SMALL CELL LUNG CARCINOMA, 16.66%) FROM PATIENTS, BUT ALSO IN ADJACENT NON-CANCEROUS TISSUE (45.71%). CONCORDANCE OF P16 METHYLATION AND POSITIVITY BY CYTOLOGICAL EXAMINATION WAS 51.78%. METHYLATION WAS ALSO OBSERVED IN SPUTUM FROM ASYMPTOMATIC CYTOLOGY-NEGATIVE SMOKERS (22.5%) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS (THREE OF EIGHT). AMONG DISEASE-FREE INDIVIDUALS, METHYLATION CORRELATED ONLY WITH HEAVY SMOKING (>50 PACK-YEARS, P<0.001) AND DIFFERED AMONG MALE AND FEMALE DISEASE-FREE SMOKERS. IN SUMMARY, P16 METHYLATION IS VERY FREQUENT AMONG NON-SMALL CELL LUNG CARCINOMA PATIENTS, AND CORRELATES WITH HEAVY CIGARETTE CONSUMPTION ONLY IN DISEASE-FREE SMOKERS. 2007 3 137 37 ABERRANT DNA METHYLATION AND EXPRESSION OF SPDEF AND FOXA2 IN AIRWAY EPITHELIUM OF PATIENTS WITH COPD. BACKGROUND: GOBLET CELL METAPLASIA, A COMMON FEATURE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), IS ASSOCIATED WITH MUCUS HYPERSECRETION WHICH CONTRIBUTES TO THE MORBIDITY AND MORTALITY AMONG PATIENTS. TRANSCRIPTION FACTORS SAM-POINTED DOMAIN-CONTAINING ETS-LIKE FACTOR (SPDEF) AND FORKHEAD BOX PROTEIN A2 (FOXA2) REGULATE GOBLET CELL DIFFERENTIATION. THIS STUDY AIMED TO (1) INVESTIGATE DNA METHYLATION AND EXPRESSION OF SPDEF AND FOXA2 DURING GOBLET CELL DIFFERENTIATION AND (2) COMPARE THIS IN AIRWAY EPITHELIAL CELLS FROM PATIENTS WITH COPD AND CONTROLS DURING MUCOCILIARY DIFFERENTIATION. METHODS: TO ASSESS DNA METHYLATION AND EXPRESSION OF SPDEF AND FOXA2 DURING GOBLET CELL DIFFERENTIATION, PRIMARY AIRWAY EPITHELIAL CELLS, ISOLATED FROM TRACHEA (NON-COPD CONTROLS) AND BRONCHIAL TISSUE (PATIENTS WITH COPD), WERE DIFFERENTIATED BY CULTURE AT THE AIR-LIQUID INTERFACE (ALI) IN THE PRESENCE OF CYTOKINE INTERLEUKIN (IL)-13 TO PROMOTE GOBLET CELL DIFFERENTIATION. RESULTS: WE FOUND THAT SPDEF EXPRESSION WAS INDUCED DURING GOBLET CELL DIFFERENTIATION, WHILE FOXA2 EXPRESSION WAS DECREASED. IMPORTANTLY, CPG NUMBER 8 IN THE SPDEF PROMOTER WAS HYPERMETHYLATED UPON DIFFERENTIATION, WHEREAS DNA METHYLATION OF FOXA2 PROMOTER WAS NOT CHANGED. IN THE ABSENCE OF IL-13, COPD-DERIVED ALI-CULTURED CELLS DISPLAYED HIGHER SPDEF EXPRESSION THAN CONTROL-DERIVED ALI CULTURES, WHEREAS NO DIFFERENCE WAS FOUND FOR FOXA2 EXPRESSION. THIS WAS ACCOMPANIED WITH HYPOMETHYLATION OF CPG NUMBER 6 IN THE SPDEF PROMOTER AND ALSO HYPOMETHYLATION OF CPG NUMBERS 10 AND 11 IN THE FOXA2 PROMOTER. CONCLUSIONS: THESE FINDINGS SUGGEST THAT ABERRANT DNA METHYLATION OF SPDEF AND FOXA2 IS ONE OF THE FACTORS UNDERLYING MUCUS HYPERSECRETION IN COPD, OPENING NEW AVENUES FOR EPIGENETIC-BASED INHIBITION OF MUCUS HYPERSECRETION. 2017 4 3497 40 IDENTIFICATION OF NOVEL EPIGENETIC ABNORMALITIES AS SPUTUM BIOMARKERS FOR LUNG CANCER RISK AMONG SMOKERS AND COPD PATIENTS. OBJECTIVES: SMOKING IS A COMMON RISK FACTOR FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND LUNG CANCER. ALTHOUGH COPD PATIENTS HAVE HIGHER RISK OF LUNG CANCER COMPARED TO NON-COPD SMOKERS, THE MOLECULAR LINKS BETWEEN THESE DISEASES ARE NOT WELL-DEFINED. THIS STUDY AIMS TO IDENTIFY GENES THAT ARE DOWNREGULATED BY CIGARETTE SMOKE AND COMMONLY REPRESSED IN COPD AND LUNG CANCER. MATERIALS AND METHODS: PRIMARY HUMAN AIRWAY EPITHELIAL CELLS (HAEC) WERE EXPOSED TO CIGARETTE-SMOKE-EXTRACT (CSE) FOR 10-WEEKS AND SIGNIFICANTLY SUPPRESSED GENES WERE IDENTIFIED BY TRANSCRIPTOME ARRAY. EPIGENETIC ABNORMALITIES OF THESE GENES IN LUNG ADENOCARCINOMA (LUAD) FROM PATIENTS WITH OR WITHOUT COPD WERE DETERMINED USING GENOME-WIDE AND GENE-SPECIFIC ASSAYS AND BY IN VITRO TREATMENT OF CELL LINES WITH TRICHOSTATIN-A OR 5-AZA-2-DEOXYCYTIDINE. RESULTS: THE TEN MOST COMMONLY DOWNREGULATED GENES FOLLOWING CHRONIC CSE EXPOSURE OF HAEC AND SHOW PROMOTER HYPERMETHYLATION IN LUAD WERE SELECTED. AMONG THESE, EXPRESSION OF CCNA1, SNCA, AND ZNF549 WAS SIGNIFICANTLY REDUCED IN LUNG TISSUES FROM COPD COMPARED WITH NON-COPD CASES WHILE EXPRESSION OF CCNA1 AND SNCA WAS FURTHER DOWNREGULATED IN TUMORS WITH COPD. THE PROMOTER REGIONS OF ALL THREE GENES WERE HYPERMETHYLATED IN LUAD BUT NOT NORMAL OR COPD LUNGS. THE REDUCED EXPRESSION AND ABERRANT PROMOTER HYPERMETHYLATION OF THESE GENES IN LUAD WERE INDEPENDENTLY VALIDATED USING DATA FROM THE CANCER GENOME ATLAS PROJECT. IMPORTANTLY, SNCA AND ZNF549 METHYLATION DETECTED IN SPUTUM DNA FROM LUAD (52% AND 38%) CASES WERE MORE PREVALENT COMPARED TO CANCER-FREE SMOKERS (26% AND 15%), RESPECTIVELY (P < 0.02). CONCLUSIONS: OUR DATA SHOW THAT SUPPRESSION OF CCNA1, SNCA, AND ZNF549 IN LUNG CANCER AND COPD OCCURS WITH OR WITHOUT PROMOTER HYPERMETHYLATION, RESPECTIVELY. DETECTING METHYLATION OF THESE AND PREVIOUSLY IDENTIFIED GENES IN SPUTUM OF CANCER-FREE SMOKERS MAY SERVE AS NON-INVASIVE BIOMARKERS FOR EARLY DETECTION OF LUNG CANCER AMONG HIGH RISK SMOKERS INCLUDING COPD PATIENTS. 2020 5 3449 36 HYPERMETHYLATION OF THE NRF2 PROMOTER INDUCES FERROPTOSIS BY INHIBITING THE NRF2-GPX4 AXIS IN COPD. BACKGROUND: NUCLEAR FACTOR E2-RELATED FACTOR 2 (NRF2) IS INVOLVED IN OXIDATIVE STRESS AND LUNG INFLAMMATION AND REGULATES THE ETIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). FERROPTOSIS IS CHARACTERIZED BY THE ACCUMULATION OF LIPID REACTIVE OXYGEN SPECIES (ROS) VIA FERROUS ION-DEPENDENT FENTON REACTIONS AND IS INVOLVED IN COPD. HOWEVER, THE ROLE OF NRF2 IN FERROPTOSIS AND ITS EPIGENETIC REGULATION IN THE PATHOGENESIS OF COPD REMAIN UNCLEAR. METHODS: FERROPTOSIS WAS DETECTED BY 4-HNE, MDA, C11BODIPY, DCFH-DA, PEALS' STAINING AND CCK-8 ASSAYS. QPCR AND WESTERN BLOTTING WERE PERFORMED TO EXAMINE THE NRF2 LEVELS IN PERIPHERAL LUNG TISSUES, PRIMARY EPITHELIAL CELLS COLLECTED FROM PATIENTS WITH COPD AND SUBJECTS WITH NORMAL PULMONARY FUNCTION (NEVER-SMOKER [CONTROL-NS]; SMOKER [CONTROL-S]), AND CIGARETTE SMOKE EXTRACT (CSE)-TREATED HUMAN BRONCHIAL EPITHELIAL (HBE) CELLS. ELISA WAS USED TO QUANTIFY IL-8 AND IL-1BETA LEVELS. METHYLATION OF THE NRF2 PROMOTER WAS ANALYZED BY BISULFITE SEQUENCING AND PYROSEQUENCING. RESULTS: FERROPTOSIS WAS INVOLVED IN COPD AND GLUTATHIONE PEROXIDASE 4 (GPX4) EXPRESSION WAS DOWNREGULATED IN THE COPD GROUP. REACTIVE OXYGEN SPECIES (ROS), LIPID PEROXIDES AND MDA WERE INCREASED, BUT GPX4 AND SOD WERE EXHAUSTED IN CSE-TREATED HBE CELLS. THE PRODUCTION OF IL-1BETA AND IL-8 WAS PROMOTED IN HBE CELLS IN RESPONSE TO CSE BUT COULD BE REVERSED BY THE FERROPTOSIS INHIBITOR FER-1. THE NRF2 LEVEL WAS SIGNIFICANTLY DECREASED IN THE COPD GROUP COMPARED WITH THE CONTROL-S AND CONTROL-NS GROUPS. INCREASED NRF2 EXPRESSION ENHANCED GPX4 AND SOD LEVELS AND INHIBITED FERROPTOSIS AND PROINFLAMMATORY CYTOKINES IN THE SUPERNATANT. INHIBITION OF GPX4 REVERSED THE EFFECT OF NRF2 OVEREXPRESSION AND PROMOTED FERROPTOSIS. TWO SPECIFIC CPG SITES WITHIN THE NRF2 PROMOTER WERE HYPERMETHYLATED IN THE COPD GROUP. SIMILARLY, CSE-TREATED HBE CELLS EXHIBITED HYPERMETHYLATION OF THE NRF2 GENE. CONCLUSION: NRF2 EXPRESSION WAS DOWNREGULATED IN THE LUNGS OF COPD PATIENTS DUE TO HYPERMETHYLATION OF THE NRF2 PROMOTER, INHIBITING NRF2/GPX4 AND FERROPTOSIS, WHICH IS RELATED TO THE INITIATION AND PROGRESSION OF COPD. TARGETING NRF2/GPX4 MAY INHIBIT FERROPTOSIS, WHICH COULD PROVIDE STRATEGIES TO DELAY OR TREAT COPD. 2021 6 5422 36 REGULATION OF LUNG EPITHELIAL CELL SENESCENCE IN SMOKING-INDUCED COPD/EMPHYSEMA BY MICROR-125A-5P VIA SP1 MEDIATION OF SIRT1/HIF-1A. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AFFECTS THE HEALTH OF MORE THAN 300 MILLION PEOPLE WORLDWIDE; AT PRESENT, THERE IS NO EFFECTIVE DRUG TO TREAT COPD. SMOKING IS THE MOST IMPORTANT RISK FACTOR, BUT THE MOLECULAR MECHANISM BY WHICH SMOKING CAUSES THE DISEASE IS UNCLEAR. THE SENESCENCE OF LUNG EPITHELIAL CELLS IS RELATED TO DEVELOPMENT OF COPD. REGULATION OF MIRNAS IS THE MAIN EPIGENETIC MECHANISM RELATED TO AGING. BETA-GALACTOSE STAINING SHOWED THAT THE LUNG TISSUES OF SMOKERS HAVE A HIGHER DEGREE OF CELLULAR SENESCENCE, AND THE EXPRESSION OF MIR-125A-5P IS HIGH. THIS EFFECT IS OBVIOUS FOR SMOKERS WITH COPD/EMPHYSEMA, AND THERE IS A NEGATIVE CORRELATION BETWEEN MIR-125A-5P LEVELS AND VALUES FOR FORCED EXPIRATORY VOLUME IN ONE SECOND (FEV1)/FORCED VITAL CAPACITY (FVC). AFTER BALB/C MICE WERE CHRONICALLY EXPOSED TO VARIOUS CONCENTRATIONS OF CIGARETTE SMOKE (CS), PLETHYSMOGRAPHY SHOWED THAT LUNG FUNCTION WAS IMPAIRED, LUNG TISSUE SENESCENCE WAS INCREASED, AND THE SENESCENCE-ASSOCIATED SECRETORY PHENOTYPE (SASP) IN BRONCHOALVEOLAR LAVAGE FLUID WAS INCREASED. FOR MOUSE LUNG EPITHELIAL (MLE)-12 CELLS TREATED WITH CIGARETTE SMOKE EXTRACT (CSE), SP1 AND SIRT1 LEVELS WERE LOW, HIF-1ALPHA ACETYLATION LEVELS WERE HIGH, AND CELL SENESCENCE AND SECRETION OF SASP FACTORS WERE ELEVATED. DOWN-REGULATION OF MIR-125A-5P OR UP-REGULATION OF SP1 REVERSED THESE EFFECTS. IN ADDITION, COMPARED WITH MICE EXPOSED TO CS, KNOCKDOWN OF MIR-125A-5P REDUCED LUNG EPITHELIAL CELL SENESCENCE AND COPD/EMPHYSEMA. THEREFORE, IN SMOKING-INDUCED COPD, ELEVATED MIR-125A-5P PARTICIPATES IN THE SENESCENCE OF LUNG EPITHELIAL CELLS THROUGH SP1/SIRT1/HIF-1ALPHA. THESE FINDINGS PROVIDE EVIDENCE RELATED TO THE PATHOGENESIS OF COPD/EMPHYSEMA CAUSED BY CHRONIC SMOKING. 2022 7 304 41 AIRWAY AGING AND METHYLATION DISRUPTIONS IN HIV-ASSOCIATED CHRONIC OBSTRUCTIVE PULMONARY DISEASE. RATIONALE: AGE-RELATED DISEASES LIKE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OCCUR AT HIGHER RATES IN PEOPLE LIVING WITH HUMAN IMMUNODEFICIENCY VIRUS (PLWH) THAN IN UNINFECTED POPULATIONS. OBJECTIVES: TO IDENTIFY WHETHER ACCELERATED AGING CAN BE OBSERVED IN THE AIRWAYS OF PLWH WITH COPD, MANIFEST BY A UNIQUE DNA METHYLATION SIGNATURE. METHODS: BRONCHIAL EPITHELIAL BRUSHINGS FROM PLWH WITH AND WITHOUT COPD AND HIV-UNINFECTED ADULTS WITH AND WITHOUT COPD (N = 76) WERE PROFILED FOR DNA METHYLATION AND GENE EXPRESSION. WE EVALUATED GLOBAL ALU AND LINE-1 METHYLATION AND CALCULATED THE EPIGENETIC AGE USING THE HORVATH CLOCK AND THE METHYLATION TELOMERE LENGTH ESTIMATOR. TO IDENTIFY GENOME-WIDE DIFFERENTIAL DNA METHYLATION AND GENE EXPRESSION ASSOCIATED WITH HIV AND COPD, ROBUST LINEAR MODELS WERE USED FOLLOWED BY AN EXPRESSION QUANTITATIVE TRAIT METHYLATION (EQTM) ANALYSIS. MEASUREMENTS AND MAIN RESULTS: EPIGENETIC AGE ACCELERATION AND SHORTER METHYLATION ESTIMATES OF TELOMERE LENGTH WERE FOUND IN PLWH WITH COPD COMPARED WITH PLWH WITHOUT COPD AND UNINFECTED PATIENTS WITH AND WITHOUT COPD. GLOBAL HYPOMETHYLATION WAS IDENTIFIED IN PLWH. WE IDENTIFIED 7,970 CYTOSINE BASES LOCATED NEXT TO A GUANINE BASE (CPG SITES), 293 GENES, AND 9 EXPRESSION QUANTITATIVE TRAIT METHYLATION-GENE PAIRS ASSOCIATED WITH THE INTERACTION BETWEEN HIV AND COPD. ACTIN BINDING LIM PROTEIN FAMILY MEMBER 3 (ABLIM3) WAS ONE OF THE NOVEL CANDIDATE GENES FOR HIV-ASSOCIATED COPD HIGHLIGHTED BY OUR ANALYSIS. CONCLUSIONS: METHYLATION AGE ACCELERATION IS OBSERVED IN THE AIRWAY EPITHELIUM OF PLWH WITH COPD, A PROCESS THAT MAY BE RESPONSIBLE FOR THE HEIGHTENED RISK OF COPD IN THIS POPULATION. THEIR DISTINCT METHYLATION PROFILE, DIFFERING FROM THAT OBSERVED IN PATIENTS WITH COPD ALONE, SUGGESTS A UNIQUE PATHOGENESIS TO HIV-ASSOCIATED COPD. THE ASSOCIATIONS WARRANT FURTHER INVESTIGATION TO ESTABLISH CAUSALITY. 2022 8 3447 29 HYPERMETHYLATION OF MITOCHONDRIAL TRANSCRIPTION FACTOR A INDUCED BY CIGARETTE SMOKE IS ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. PURPOSE OF THE STUDY: CIGARETTE SMOKING IS A LEADING ENVIRONMENTAL CONTRIBUTOR TO CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BUT ITS EPIGENETIC REGULATION OF MTTFA GENE REMAINS ELUSIVE. THIS STUDY AIMS TO EXPLORE THE RELATIONSHIP OF DNA METHYLATION OF MTTFA AND CIGARETTE SMOKING IN COPD. MATERIALS AND METHODS: WE ANALYZED DNA METHYLATION ON MTTFA PROMOTERS IN CLINICAL SAMPLES FROM COPD PATIENTS AND SUBJECTS WITH NORMAL PULMONARY FUNCTION. EXPRESSION OF MTTFA MRNA IN THE CLINICAL SAMPLES AND MTTFA MRNA AND PROTEIN IN HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS(HUVECS) TREATED WITH CIGARETTE SMOKE EXTRACT (CSE) WAS EVALUATED. MTTFA MRNA AND PROTEIN LEVELS WERE MEASURED TO DETERMINE EFFECTS OF DEMETHYLATION AGENTS ON CSE-TREATED HUVECS. RESULTS: THE DNA METHYLATION LEVEL OF THE MTTFA PROMOTER WAS SIGNIFICANTLY INCREASED IN COPD GROUP. EXPRESSION OF MTTFA MRNA WAS DOWNREGULATED IN THE LUNGS AS A CONSEQUENCE OF HYPERMETHYLATION OF MTTFA PROMOTER. EXPRESSION OF MTTFA MRNA AND PROTEIN WAS DOWNREGULATED IN CSE-TREATED HUVECS AS A CONSEQUENCE OF HYPERMETHYLATION OF THE MTTFA PROMOTER. MTTFA EXPRESSION IN CSE-TREATED HUVECS WAS RESTORED BY THE METHYLATION INHIBITOR, 5-AZA-2'-DEOXYCYTIDINE(AZA). CONCLUSIONS: CIGARETTE SMOKE-INDUCED HYPERMETHYLATION OF THE MTTFA PROMOTER IS RELATED TO THE INITIATION AND PROGRESSION OF COPD. OUR FINDING MAY PROVIDE A NEW STRATEGY FOR THE INTERVENTION OF COPD BY DEVELOPING DEMETHYLATION AGENTS TARGETING MTTFA HYPERMETHYLATION. 2019 9 1550 28 DNA METHYLATION IS ASSOCIATED WITH AIRFLOW OBSTRUCTION IN PATIENTS LIVING WITH HIV. INTRODUCTION: PEOPLE LIVING WITH HIV (PLWH) SUFFER FROM AGE-RELATED COMORBIDITIES SUCH AS COPD. THE PROCESSES RESPONSIBLE FOR REDUCED LUNG FUNCTION IN PLWH ARE LARGELY UNKNOWN. WE PERFORMED AN EPIGENOME-WIDE ASSOCIATION STUDY TO INVESTIGATE WHETHER BLOOD DNA METHYLATION IS ASSOCIATED WITH IMPAIRED LUNG FUNCTION IN PLWH. METHODS: USING BLOOD DNA METHYLATION PROFILES FROM 161 PLWH, WE TESTED THE EFFECT OF METHYLATION ON FEV(1), FEV(1)/FVC RATIO AND FEV(1) DECLINE OVER A MEDIAN OF 5 YEARS. WE EVALUATED THE GLOBAL METHYLATION OF PLWH WITH AIRFLOW OBSTRUCTION BY TESTING THE DIFFERENTIAL METHYLATION OF TRANSPOSABLE ELEMENTS ALU AND LINE-1, A WELL-DESCRIBED MARKER OF EPIGENETIC AGEING. RESULTS: AIRFLOW OBSTRUCTION AS DEFINED BY A FEV(1)/FVC<0.70 WAS ASSOCIATED WITH 1393 DIFFERENTIALLY METHYLATED POSITIONS (DMPS), WHILE 4676 WERE ASSOCIATED WITH AIRFLOW OBSTRUCTION BASED ON THE FEV(1)/FVC 20 PACK-YEARS) WERE INVESTIGATED FOR MUTATIONS IN THE K-RAS (CODON 12) AND P53 (CODONS 248, 249, AND 273) GENES AND FOR ALLELIC HYPERMETHYLATION OF THE P16(INK4A) GENE. DNA WAS ISOLATED FROM SPUTUM AND BILATERAL BRONCHIAL LAVAGE, AND BRUSHINGS WERE TAKEN AT BRONCHOSCOPY. RESULTS: FORTY-ONE GENETIC LESIONS WERE DETECTED WITHIN EXFOLIATIVE MATERIAL FROM THE GROUP OF 51 PATIENTS WITH LUNG CANCER AND 10 LESIONS IN THE CHRONIC SMOKER GROUP. K-RAS MUTATIONS OCCURRED EXCLUSIVELY IN THE LUNG CANCER GROUP, WHEREAS P53 MUTATIONS AND P16(INK4A) PROMOTER HYPERMETHYLATION WERE ALSO FOUND IN CHRONIC SMOKERS. THREE OF EIGHT CHRONIC SMOKERS WHO HARBORED AN (EPI)GENETIC ALTERATION WERE SUBSEQUENTLY DIAGNOSED WITH LUNG CANCER. ANALYSIS OF SPUTUM YIELDED INFORMATION EQUIVALENT TO THAT OF SAMPLES OBTAINED DURING BRONCHOSCOPY. CONCLUSION: P16(INK4A) PROMOTER HYPERMETHYLATION AND P53 MUTATIONS CAN OCCUR IN CHRONIC SMOKERS BEFORE ANY CLINICAL EVIDENCE OF NEOPLASIA AND MAY BE INDICATIVE OF AN INCREASED RISK OF DEVELOPING LUNG CANCER OR OF EARLY DISEASE. K-RAS MUTATIONS OCCUR EXCLUSIVELY IN THE PRESENCE OF CLINICALLY DETECTABLE NEOPLASTIC TRANSFORMATION. MOLECULAR ANALYSIS OF SPUTUM FOR SUCH MARKERS MAY PROVIDE AN EFFECTIVE MEANS OF SCREENING CHRONIC SMOKERS TO ENABLE EARLIER DETECTION AND THERAPEUTIC INTERVENTION OF LUNG CANCER. 2000 13 4899 24 OXIDATIVE STRESS MEDIATES THE APOPTOSIS AND EPIGENETIC MODIFICATION OF THE BCL-2 PROMOTER VIA DNMT1 IN A CIGARETTE SMOKE-INDUCED EMPHYSEMA MODEL. BACKGROUND: EMPHYSEMA IS A CRUCIAL PATHOLOGICAL CHARACTERISTIC OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). OXIDATIVE STRESS, APOPTOSIS AND EPIGENETIC MECHANISMS CONTRIBUTE TO THE PATHOGENESIS OF EMPHYSEMA. HOWEVER, AN ATTEMPT TO ACCURATELY IDENTIFY WHETHER THESE MECHANISMS INTERACT WITH EACH OTHER AND HOW THEY ARE TRIGGERED HAS NEVER BEEN CONDUCTED. METHOD: THE TOTAL REACTIVE OXYGEN SPECIES (ROS) LEVEL, PULMONARY APOPTOSIS AND B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) EXPRESSION, AN APOPTOSIS REGULATOR, WERE DETECTED IN SAMPLES FROM COPD PATIENTS. BISULFITE SEQUENCING PCR (BSP) WAS CONDUCTED TO OBSERVE THE ALTERATIONS IN THE METHYLATION OF THE BCL-2 PROMOTER IN SPECIMENS. THE DYSREGULATION OF DNA METHYLTRANSFERASE ENZYME 1 (DNMT1), A VITAL DNA METHYLTRANSFERASE ENZYME, IN THE LUNGS OF PATIENTS WAS CONFIRMED THROUGH WESTERN BLOTTING. TO FIND OUT INTERACTIONS BETWEEN OXIDATIVE STRESS AND DNA METHYLATION IN EMPHYSEMA, MOUSE MODELS WERE BUILT WITH ANTIOXIDANT TREATMENT AND DNMT1 SILENCING, AND WERE EXAMINED WITH THE PULMONARY APOPTOSIS, BCL-2 AND DNMT1 LEVELS, AND EPIGENETIC ALTERATIONS OF BCL-2. RESULTS: HIGHER ROS LEVELS AND PULMONARY APOPTOSIS WERE OBSERVED IN COPD PATIENTS THAN IN HEALTHY CONTROLS. DOWNREGULATED BCL-2 EXPRESSION WITH INCREASED PROMOTER METHYLATION AND DNMT1 PROTEIN EXPRESSION WAS FOUND IN COPD PATIENTS. ANTIOXIDANT TREATMENT REDUCED THE LEVEL OF ROS, DNMT1 PROTEIN AND EMPHYSEMATOUS PROGRESSION IN THE SMOKING MODELS. FOLLOWING DNMT1 BLOCKADE, SMOKING MODELS SHOWED IMPROVED LUNG FUNCTION, PULMONARY APOPTOSIS, EMPHYSEMATOUS PROGRESSION, AND INCREASED BCL-2 PROTEIN LEVEL WITH LESS PROMOTER METHYLATION THAN EMPHYSEMA MICE. CONCLUSION: CIGARETTE-INDUCED OXIDATIVE STRESS MEDIATES PULMONARY APOPTOSIS AND HYPERMETHYLATION OF THE BCL-2 PROMOTER IN EMPHYSEMA MODELS THROUGH DNMT1. 2020 14 1551 37 DNA METHYLATION IS GLOBALLY DISRUPTED AND ASSOCIATED WITH EXPRESSION CHANGES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE SMALL AIRWAYS. DNA METHYLATION IS AN EPIGENETIC MODIFICATION THAT IS HIGHLY DISRUPTED IN RESPONSE TO CIGARETTE SMOKE AND INVOLVED IN A WIDE SPECTRUM OF MALIGNANT AND NONMALIGNANT DISEASES, BUT SURPRISINGLY NOT PREVIOUSLY ASSESSED IN SMALL AIRWAYS OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). SMALL AIRWAYS ARE THE PRIMARY SITES OF AIRFLOW OBSTRUCTION IN COPD. WE SOUGHT TO DETERMINE WHETHER DNA METHYLATION PATTERNS ARE DISRUPTED IN SMALL AIRWAY EPITHELIA OF PATIENTS WITH COPD, AND EVALUATE WHETHER CHANGES IN GENE EXPRESSION ARE ASSOCIATED WITH THESE DISRUPTIONS. GENOME-WIDE METHYLATION AND GENE EXPRESSION ANALYSIS WERE PERFORMED ON SMALL AIRWAY EPITHELIAL DNA AND RNA OBTAINED FROM THE SAME PATIENT DURING BRONCHOSCOPY, USING ILLUMINA'S INFINIUM HM27 AND AFFYMETRIX'S GENECHIP HUMAN GENE 1.0 ST ARRAYS. TO CONTROL FOR KNOWN EFFECTS OF CIGARETTE SMOKING ON DNA METHYLATION, METHYLATION AND GENE EXPRESSION PROFILES WERE COMPARED BETWEEN FORMER SMOKERS WITH AND WITHOUT COPD MATCHED FOR AGE, PACK-YEARS, AND YEARS OF SMOKING CESSATION. OUR RESULTS INDICATE THAT ABERRANT DNA METHYLATION IS (1) A GENOME-WIDE PHENOMENON IN SMALL AIRWAYS OF PATIENTS WITH COPD, AND (2) ASSOCIATED WITH ALTERED EXPRESSION OF GENES AND PATHWAYS IMPORTANT TO COPD, SUCH AS THE NF-E2-RELATED FACTOR 2 OXIDATIVE RESPONSE PATHWAY. DNA METHYLATION IS LIKELY AN IMPORTANT MECHANISM CONTRIBUTING TO MODULATION OF GENES IMPORTANT TO COPD PATHOLOGY. BECAUSE THESE METHYLATION EVENTS MAY UNDERLIE DISEASE-SPECIFIC GENE EXPRESSION CHANGES, THEIR CHARACTERIZATION IS A CRITICAL FIRST STEP TOWARD THE DEVELOPMENT OF EPIGENETIC MARKERS AND AN OPPORTUNITY FOR DEVELOPING NOVEL EPIGENETIC THERAPEUTIC INTERVENTIONS FOR COPD. 2014 15 6440 22 THERAPEUTIC APPROACHES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) EXACERBATIONS. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS A PROGRESSIVE PULMONARY DISORDER UNDERPINNED BY POORLY REVERSIBLE AIRFLOW RESULTING FROM CHRONIC BRONCHITIS OR EMPHYSEMA. THE PREVALENCE AND MORTALITY OF COPD CONTINUE TO INCREASE. PHARMACOTHERAPY FOR PATIENTS WITH COPD HAS INCLUDED ANTIBIOTICS, BRONCHODILATORS, AND ANTI-INFLAMMATORY CORTICOSTEROIDS (BUT WITH LITTLE SUCCESS). ORAL DISEASES HAVE LONG BEEN ESTABLISHED AS CLINICAL RISK FACTORS FOR DEVELOPING RESPIRATORY DISEASES. THE ESTABLISHMENT OF A VERY SIMILAR MICROBIOME IN THE MOUTH AND THE LUNG CONFIRMS THE ORAL-LUNG CONNECTION. THE ASPIRATION OF PATHOGENIC MICROBES FROM THE ORAL CAVITY HAS BEEN IMPLICATED IN SEVERAL RESPIRATORY DISEASES, INCLUDING PNEUMONIA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). THIS REVIEW FOCUSES ON CURRENT AND FUTURE PHARMACOTHERAPEUTIC APPROACHES FOR COPD EXACERBATION INCLUDING ANTIMICROBIALS, MUCOREGULATORS, THE USE OF BRONCHODILATORS AND ANTI-INFLAMMATORY DRUGS, MODIFYING EPIGENETIC MARKS, AND MODULATING DYSBIOSIS OF THE MICROBIOME. 2022 16 756 32 CARM1 REGULATES SENESCENCE DURING AIRWAY EPITHELIAL CELL INJURY IN COPD PATHOGENESIS. CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS A LIFE-THREATENING LUNG DISEASE. ALTHOUGH CIGARETTE SMOKE WAS CONSIDERED THE MAIN CAUSE OF DEVELOPMENT, THE HETEROGENEOUS NATURE OF THE DISEASE LEAVES IT UNCLEAR WHETHER OTHER FACTORS CONTRIBUTE TO THE PREDISPOSITION OR IMPAIRED REGENERATION RESPONSE OBSERVED. RECENTLY, EPIGENETIC MODIFICATION HAS EMERGED TO BE A KEY PLAYER IN THE PATHOGENESIS OF COPD. THE ADDITION OF METHYL GROUPS TO ARGININE RESIDUES IN BOTH HISTONE AND NONHISTONE PROTEINS BY PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) IS AN IMPORTANT POSTTRANSLATIONAL EPIGENETIC MODIFICATION EVENT REGULATING CELLULAR PROLIFERATION, DIFFERENTIATION, APOPTOSIS, AND SENESCENCE. HERE, WE HYPOTHESIZE THAT COACTIVATOR-ASSOCIATED ARGININE METHYLTRANSFERASE-1 (CARM1) REGULATES AIRWAY EPITHELIAL CELL INJURY IN COPD PATHOGENESIS BY CONTROLLING CELLULAR SENESCENCE. USING THE NAPHTHALENE (NA)-INDUCED MOUSE MODEL OF AIRWAY EPITHELIAL DAMAGE, WE DEMONSTRATE THAT LOSS OF CC10-POSITIVE CLUB CELLS IS ACCOMPANIED BY A REDUCTION IN CARM1-EXPRESSING CELLS OF THE AIRWAY EPITHELIUM. FURTHERMORE, CARM1 HAPLOINSUFFFICENT MICE SHOWED PERTURBED CLUB CELL REGENERATION FOLLOWING NA TREATMENT. IN ADDITION, CARM1 REDUCTION LED TO DECREASED NUMBERS OF ANTISENESCENT SIRTUIN 1-EXPRESSING CELLS ACCOMPANIED BY HIGHER P21, P16, AND BETA-GALACTOSIDASE-POSITIVE SENESCENT CELLS IN THE MOUSE AIRWAY FOLLOWING NA TREATMENT. IMPORTANTLY, CARM1-SILENCED HUMAN BRONCHIAL EPITHELIAL CELLS SHOWED IMPAIRED WOUND HEALING AND HIGHER BETA-GALACTOSIDASE ACTIVITY. THESE RESULTS DEMONSTRATE THAT CARM1 CONTRIBUTES TO AIRWAY REPAIR AND REGENERATION BY REGULATING AIRWAY EPITHELIAL CELL SENESCENCE. 2019 17 1591 39 DNA METHYLATION PROFILING IN PERIPHERAL LUNG TISSUES OF SMOKERS AND PATIENTS WITH COPD. BACKGROUND: EPIGENETICS CHANGES HAVE BEEN SHOWN TO BE AFFECTED BY CIGARETTE SMOKING. CIGARETTE SMOKE (CS)-MEDIATED DNA METHYLATION CAN POTENTIALLY AFFECT SEVERAL CELLULAR AND PATHOPHYSIOLOGICAL PROCESSES, ACUTE EXACERBATIONS, AND COMORBIDITY IN THE LUNGS OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). WE SOUGHT TO DETERMINE WHETHER GENOME-WIDE LUNG DNA METHYLATION PROFILES OF SMOKERS AND PATIENTS WITH COPD WERE SIGNIFICANTLY DIFFERENT FROM NON-SMOKERS. WE ISOLATED DNA FROM PARENCHYMAL LUNG TISSUES OF PATIENTS INCLUDING EIGHT LIFELONG NON-SMOKERS, EIGHT CURRENT SMOKERS, AND EIGHT PATIENTS WITH COPD AND ANALYZED THE SAMPLES USING ILLUMINA'S INFINIUM HUMANMETHYLATION450 BEADCHIP. RESULTS: OUR DATA REVEALED THAT THE DIFFERENTIALLY METHYLATED GENES WERE RELATED TO TOP CANONICAL PATHWAYS (E.G., G BETA GAMMA SIGNALING, MECHANISMS OF CANCER, AND NNOS SIGNALING IN NEURONS), DISEASE AND DISORDERS (ORGANISMAL INJURY AND ABNORMALITIES, CANCER, AND RESPIRATORY DISEASE), AND MOLECULAR AND CELLULAR FUNCTIONS (CELL DEATH AND SURVIVAL, CELLULAR ASSEMBLY AND ORGANIZATION, CELLULAR FUNCTION AND MAINTENANCE) IN PATIENTS WITH COPD. THE GENOME-WIDE DNA METHYLATION ANALYSIS IDENTIFIED SUGGESTIVE GENES, SUCH AS NOS1AP, TNFAIP2, BID, GABRB1, ATXN7, AND THOC7 WITH DNA METHYLATION CHANGES IN COPD LUNG TISSUES THAT WERE FURTHER VALIDATED BY PYROSEQUENCING. PYROSEQUENCING VALIDATION CONFIRMED HYPER-METHYLATION IN SMOKERS AND PATIENTS WITH COPD AS COMPARED TO NON-SMOKERS. HOWEVER, WE DID NOT DETECT SIGNIFICANT DIFFERENCES IN DNA METHYLATION FOR TNFAIP2, ATXN7, AND THOC7 GENES IN SMOKERS AND COPD GROUPS DESPITE THE CHANGES OBSERVED IN THE GENOME-WIDE ANALYSIS. CONCLUSIONS: OUR STUDY SUGGESTS THAT DNA METHYLATION IN SUGGESTIVE GENES, SUCH AS NOS1AP, BID, AND GABRB1 MAY BE USED AS EPIGENETIC SIGNATURES IN SMOKERS AND PATIENTS WITH COPD IF THE SAME IS VALIDATED IN A LARGER COHORT. FUTURE STUDIES ARE REQUIRED TO CORRELATE DNA METHYLATION STATUS WITH TRANSCRIPTOMICS OF SELECTIVE GENES IDENTIFIED IN THIS STUDY AND ELUCIDATE THEIR ROLE AND INVOLVEMENT IN THE PROGRESSION OF COPD AND ITS EXACERBATIONS. 2017 18 3638 42 INCREASED EXPRESSION OF BETA-DEFENSIN 1 (DEFB1) IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. ON-GOING AIRWAY INFLAMMATION IS CHARACTERISTIC FOR THE PATHOPHYSIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). HOWEVER, THE KEY FACTORS DETERMINING THE DECREASE IN LUNG FUNCTION, AN IMPORTANT CLINICAL PARAMETER OF COPD, ARE NOT CLEAR. GENOME-WIDE LINKAGE ANALYSES PROVIDE EVIDENCE FOR SIGNIFICANT LINKAGE TO AIRWAY OBSTRUCTION SUSCEPTIBILITY LOCI ON CHROMOSOME 8P23, THE LOCATION OF THE HUMAN DEFENSIN GENE CLUSTER. MOREOVER, A GENETIC VARIATION IN THE DEFENSIN BETA 1 (DEFB1) GENE WAS FOUND TO BE ASSOCIATED WITH COPD. THEREFORE, WE HYPOTHESIZED THAT DEFB1 IS DIFFERENTLY REGULATED AND EXPRESSED IN HUMAN LUNGS DURING COPD PROGRESSION. GENE EXPRESSION OF DEFB1 WAS ASSESSED IN BRONCHIAL EPITHELIUM AND BAL FLUID CELLS OF HEALTHY CONTROLS AND PATIENTS WITH COPD AND USING BISULFITE SEQUENCING AND CHIP ANALYSIS, THE EPIGENETIC CONTROL OF DEFB1 MRNA EXPRESSION WAS INVESTIGATED. WE CAN DEMONSTRATE THAT DEFB1 MRNA EXPRESSION WAS SIGNIFICANTLY INCREASED IN BRONCHOPULMONARY SPECIMEN OF PATIENTS WITH COPD (N = 34) VS. HEALTHY CONTROLS (N = 10) (P<0.0001). FURTHERMORE, A SIGNIFICANT CORRELATION COULD BE DETECTED BETWEEN DEFB1 AND FUNCTIONAL PARAMETERS SUCH AS FEV(1) (P = 0.0024) AND THE FEV(1)/VC RATIO (P = 0.0005). UPREGULATION OF DEFB1 MRNA WAS PARALLELED BY CHANGES IN HDAC1-3, HDAC5 AND HDAC8 MRNA EXPRESSION. WHEREAS BISULFITE SEQUENCING REVEALED NO DIFFERENCES IN THE METHYLATION STATE OF DEFB1 PROMOTER BETWEEN PATIENTS WITH COPD AND CONTROLS, CHIP ANALYSIS SHOWED THAT ENHANCED DEFB1 MRNA EXPRESSION WAS ASSOCIATED WITH THE ESTABLISHMENT OF AN ACTIVE HISTONE CODE. THUS, EXPRESSION OF HUMAN DEFB1 IS UPREGULATED AND RELATED TO THE DECREASE IN PULMONARY FUNCTION IN PATIENTS WITH COPD. 2011 19 6297 36 THE PROTECTIVE EFFECT OF HBO1 ON CIGARETTE SMOKE EXTRACT-INDUCED APOPTOSIS IN AIRWAY EPITHELIAL CELLS. PURPOSE: EPIGENETIC MODIFICATION IS ONE OF MOST IMPORTANT MECHANISMS UNDERLYING THE PATHOGENESIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). THE PURPOSE OF THIS STUDY WAS TO DETERMINE WHETHER HISTONE ACETYLTRANSFERASE BINDING TO ORC1 (HBO1) CAN PROTECT AGAINST CIGARETTE SMOKE (CS)-INDUCED CELL APOPTOSIS AND SUSTAIN NORMAL HISTONE ACETYLATION IN COPD. METHODS: HUMAN LUNG TISSUE SAMPLES WERE OBTAINED FROM PATIENTS WHO UNDERWENT LUNG RESECTION. THE EMPHYSEMA MOUSE MODEL AND HBO1 OVEREXPRESSING MICE WERE EACH ESTABLISHED BY INTRAPERITONEAL INJECTION WITH CIGARETTE SMOKE EXTRACT (CSE) OR INTRATRACHEAL LENTIVIRAL VECTORS INSTILLATION. TUNEL (TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE DUTP NICK END LABELING) ASSAYS WERE USED TO ASSESS APOPTOTIC RATIO IN MICE. THE APOPTOSIS OF HUMAN BRONCHIAL EPITHELIAL CELLS (HBECS) WAS ASSAYED BY FLOW CYTOMETRY. HBO1, B-CELL LYMPHOMA-2 (BCL-2), AND H3K14AC PROTEIN EXPRESSION WERE DETECTED BY WESTERN BLOTTING. HBO1 MRNA EXPRESSION WAS MEASURED BY QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION. RESULTS: PROTEIN EXPRESSION OF HBO1 WAS DECREASED SIGNIFICANTLY IN LUNG TISSUE FROM COPD PATIENTS AND CSE-TREATED EMPHYSEMA MOUSE MODELS. OVEREXPRESSION OF HBO1 ATTENUATED CSE-INDUCED EMPHYSEMATOUS CHANGES, AS WELL AS APOPTOSIS IN THE LUNGS OF COPD MICE. IN VITRO, THE HBO1 PROTEIN DEGRADED IN A TIME- AND DOSE-DEPENDENT COURSE WITH CSE TREATMENT. WITH FLOW CYTOMETRY, WE PROVED THAT HBO1 COULD REVERSE THE APOPTOSIS OF HBECS INDUCED BY CSE. FURTHERMORE, HBO1 OVEREXPRESSION PROMOTED THE EXPRESSION OF ANTI-APOPTOTIC BCL-2 PROTEIN AND ENHANCED H3K14 ACETYLATION IN AIRWAY EPITHELIAL CELLS. CONCLUSION: THESE FINDINGS DEMONSTRATE THAT THE KEY HISTONE MODULATOR HBO1 PLAYS A PROTECTIVE ROLE IN COPD PATHOGENESIS THAT MAY SHED LIGHT ON POTENTIAL THERAPEUTIC TARGETS TO INHIBIT THE PROGRESS OF COPD. 2020 20 3993 22 LONGITUDINAL FOLLOW-UP OF THE ASTHMA STATUS IN A FRENCH-CANADIAN COHORT. ASTHMA AFFECTS 340 MILLION PEOPLE WORLDWIDE AND VARIES IN TIME. TWENTY YEARS AGO, IN CANADA, THE SAGUENAY-LAC-SAINT-JEAN ASTHMA FAMILY COHORT WAS CREATED TO STUDY THE GENETIC AND ENVIRONMENTAL COMPONENTS OF ASTHMA. THIS STUDY IS A FOLLOW-UP OF 125 PARTICIPANTS OF THIS COHORT TO EXPLORE THE APPEARANCE, PERSISTENCE, AND PROGRESSION OF ASTHMA OVER 10-20 YEARS. PARTICIPANTS ANSWERED A CLINICAL STANDARDIZED QUESTIONNAIRE. LUNG FUNCTION WAS ASSESSED (FORCED EXPIRATORY VOLUME IN 1 S, FORCED VITAL CAPACITY, BRONCHIAL REVERSIBILITY, AND METHACHOLINE BRONCHOPROVOCATION), SKIN ALLERGY TESTING WAS PERFORMED, BLOOD SAMPLES WERE OBTAINED (IMMUNOGLOBULIN E, WHITE BLOOD CELL COUNTS) AND PHENOTYPES WERE COMPARED BETWEEN RECRUITMENT AND FOLLOW-UP. FROM THE PARTICIPANTS WITHOUT ASTHMA AT RECRUITMENT, 12% DEVELOPED A PHENOTYPE OF ADULT-ONSET ASTHMA WITH THE PRESENCE OF RISK FACTORS, SUCH AS ATOPY, HIGH BODY MASS INDEX, AND EXPOSURE TO SMOKING. A DECREASE OF PC(20) VALUES IN THIS GROUP WAS OBSERVED AND A DECREASE IN THE FEV(1)/FVC RATIO IN ALL GROUPS. ALSO, 7% OF INDIVIDUALS WITH ASTHMA AT RECRUITMENT DEVELOPED CHRONIC OBSTRUCTIVE PULMONARY DISEASE, PRESENTING RISK FACTORS AT RECRUITMENT, SUCH AS MODERATE-TO-SEVERE BRONCHIAL HYPERRESPONSIVENESS, EXPOSURE TO SMOKING, AND ASTHMA. THIS STUDY ALLOWED A BETTER INTERPRETATION OF THE EVOLUTION OF ASTHMA. FINE PHENOTYPIC CHARACTERIZATION IS THE FIRST STEP FOR MEANINGFUL GENETIC AND EPIGENETIC STUDIES. 2022